Company intelligence / Profile preview

Fangzhou Jianke

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

As of end 2024, Fangzhou Jianke is China's largest online chronic disease management platform, with ~49.2 million registered users and ~10.1 million monthly active users, providing both retail pharmacy and physician consultation/e-prescription services. Notably, they partner with thousands of drug manufacturers and facilitate online drug ordering, chronic disease management, and specialty medical support

Therapeutic areas: OncologyCardiovascularOther
Industry: Non-Academic Healthcare

Partnerships

5000+ Chinese pharmaceutical manufacturers, including members of the "Zhengpin Alliance" (Genuine Medicine Alliance)

Beyond the preview

Go deeper on Fangzhou Jianke.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fangzhou Jianke.

Explore the full profile